Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using...
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of...
Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of...
Health care technology executive brings more than three decades of leadership experience and a personal connection to digestive health.CHICAGO, March...
Conference call will be held today, Thursday, March 19 at 9:00 am ETCARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) --...
WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical...
End-to-end RNA optimization: Platform combines proprietary AI sequence optimization, novel genetic parts, and lab validation in application-relevant cell models to improve...
Preclinical results in therapy-resistant HER2-low breast cancer models demonstrate enhanced antitumor activity and reversal of resistance with PLK1 inhibitionSAN DIEGO,...
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
Breakthrough Therapy Designation granted to nomlabofusp for the treatment of adults and children with FA based on FDA’s review of...
Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year periodFourth Quarter Net income was $178.8 million...
NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a recognized global leader in medical cannabis and...
Results illustrate how NetraMark’s advanced AI can potentially support precision enrichment strategies in future trialsTORONTO, March 19, 2026 (GLOBE NEWSWIRE)...
Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader...
AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at...
ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2...
STAFFORD, Texas, March 19, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader...
PRI-101 inhibited aggregation of α-synuclein and actively disassembled fibrils across in vitro and in vivo models relevant to Parkinson’s disease...
Elaine Jones Chair, Board of Directors, BOOST Pharma Seasoned life science investor, executive and board leader to support next phase...